N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2b
By developing Formula I compounds, the problem of difficulty in regulating the NMDA receptor NR1/NR2B subunit activity in the prior art was solved, and effective regulation of NMDA receptor activity was achieved, with potential therapeutic effects on cognitive dysfunction and mental illness.
JP2025060835AInactive Publication Date: 2025-04-10NOVARTIS AG
Patent Information
- Application Number
- JP2024228390
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-09-26
- Filing Date
- 2024-12-25
- Publication Date
- 2025-04-10
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 2025060835000001 
Figure 2025060835000002 
Figure 2025060835000003
Abstract
To provide compositions useful in the treatment of neurological disorders.SOLUTION: Provided is a composition for use in treating a disease or disorder mediated by negative allosteric modulation or inhibition of NR2B, comprising a compound of formula I or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, the compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof being administered with another therapeutic agent, such as lithium, a stimulant, an acetylcholinesterase inhibitor, an antidepressant for low mood and irritability, an anxiolytic for anxiety, restlessness, verbal disruptive behavior, and resistance.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Tricyclic compound, preparation method thereof and pharmaceutical application thereof
CN102432598A
5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline nmdanr2b antagonists
JP2003513040A
n-alkyl-azacycloalkyl nmda / nr2b antagonists
JP2008536927A
Cyclopenta[c]pyrrole-2-carboxylic acid derivatives, their preparations, and their therapeutic applications
JP2012526783A
Tocolytic oxytocin receptor antagonists
US5726172A